Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Novel BTK inhibitor shows in vitro promise for treating mantle cell lymphoma
Key clinical point: Compound 13e showed improved anti-proliferative activities, induced strong cell apoptosis, and showed a potential safety improvement for the treatment of MCL over ibrutinib.
Major finding: Compound 13e improved anti-proliferative activities 3–40 fold in MCL cell lines and could induce strong cell apoptosis in Jeko-1 and Z138 cells. The compound also showed a potential safety improvement for the treatment of MCL.
Study details: A novel series of ibrutinib derivatives capable of potent inhibition of Bruton’s tyrosine kinase (BTK) were developed and tested in cell culture.
Disclosures: This work was supported by the key research and development project of Shandong Province, China. There were no conflicts of interest reported.
Ran F et al. Biorganic Chemistry 2020. doi.org/10.1016/j.bioorg.2019.103367.